Results 151 to 160 of about 53,092 (237)

HBV reactivation and its metabolomic profile after liver transplantation for hepatocellular carcinoma in non-alcoholic steatohepatitis. [PDF]

Chin J Cancer Res
Chen J, Chen L, Li H, Hu Z, Zhuo J, Chen X, Zhao R, He C, Wu X, Lin Z, Sun J, Wang R, Wei X, Zheng S, Xu X, Lu D.   +15 more
europepmc   +1 more source

Lipid and Foam Cell Accumulation as Novel Pathological Features of Benign Prostatic Hyperplasia

The Prostate, Volume 86, Issue 10, Page 1157-1169, July 2026.
ABSTRACT Background Benign prostatic hyperplasia (BPH) encompasses a heterogeneous set of pathological processes that instigate lower urinary tract symptoms (LUTS). Using a mouse model of steroid hormone imbalance–induced lower urinary tract dysfunction, we identified luminal lipid‐laden foamy macrophages, although their presence and contribution to ...
Dita Julianingsih, Samara V. Silver, Thaissa Horne, Kasun Gunawardena, Savannah Ward, Alicia Malewska, Douglas Strand, Julius Nyalwidhe, Ilya Sobol, Petra Popovics   +9 more
wiley   +1 more source

Hepatic encephalopathy due to non-cirrhotic portal hypertension associated with non-alcoholic steatohepatitis and chronic hepatitis B: a Case Report. [PDF]

Front Med (Lausanne)
Li H, Zhang J, Liu W, Liu Y, Yu X, Sun S.   +5 more
europepmc   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Quantitative longitudinal investigation of non-alcoholic steatohepatitis in mice by photoacoustic microscopy. [PDF]

Photoacoustics
Wei J, Zhang R, Jiang M, Gao L, Yu X, Liu X, Dai Y, Luo Q, Zhang Z, Yang X.   +9 more
europepmc   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5684-5695, July 2026.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Gardenia jasminoides fruit extract ameliorates non-alcoholic steatohepatitis with fibrosis by modulating inflammatory and fibrogenic pathways. [PDF]

PLoS One
Suttawong N, Witayavanitkul N, Chayanupatkul M, Wanpiyarat N, Werawatganone P, Siriviriyakul P, Werawatganon D.   +6 more
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5704-5714, July 2026.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Ultrafine garlic powder alleviates non-alcoholic steatohepatitis by inhibiting hepatocyte ferroptosis and modulating ERK-dependent oxidative stress. [PDF]

Front Pharmacol
Yu J, Shao N, Yang J, Yang L, Hong K, Chen Y, Zhao X, Yu H, Zhang T, Dong J.   +9 more
europepmc   +1 more source

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6184-6193, July 2026.
ABSTRACT Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care
Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo‐Pardo, Kelly Y. Chun, Toni R. Prezant, Margery A. Connelly, Jens T. Rosenberg, Joseph R. Grajo, Fernando Bril, Kenneth Cusi   +12 more
wiley   +1 more source